Compare Stocks: NAUT, PACB, SLP, and TKNO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NAUT Nautilus Biotechnology	$1.12 +20.7%	$1.23	$0.68 ▼ $4.31	$118.08M	0.87	609,787 shs	3.86 million shs
PACB Pacific Biosciences of California	$1.29 -2.3%	$1.38	$1.07 ▼ $2.73	$410.30M	2.31	6.43 million shs	4.15 million shs
SLP Simulations Plus	$18.42	$18.34	$11.09 ▼ $21.01	$372.54M	1.33	170,930 shs	181,146 shs
TKNO Alpha Teknova	$6.95 +1.0%	$6.20	$1.91 ▼ $7.84	$368.86M	0.72	259,456 shs	183,390 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NAUT Nautilus Biotechnology	+20.70%	+16.45%	+29.48%	-51.09%	+67.16%
PACB Pacific Biosciences of California	-2.27%	-2.27%	+12.17%	-4.44%	-1.53%
SLP Simulations Plus	0.00%	-0.05%	+0.38%	+11.70%	+30.08%
TKNO Alpha Teknova	+1.02%	-6.46%	+3.42%	+57.95%	+63.53%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NAUT Nautilus Biotechnology	$1.12 +20.7%	$1.23	$0.68 ▼ $4.31	$118.08M	0.87	609,787 shs	3.86 million shs
PACB Pacific Biosciences of California	$1.29 -2.3%	$1.38	$1.07 ▼ $2.73	$410.30M	2.31	6.43 million shs	4.15 million shs
SLP Simulations Plus	$18.42	$18.34	$11.09 ▼ $21.01	$372.54M	1.33	170,930 shs	181,146 shs
TKNO Alpha Teknova	$6.95 +1.0%	$6.20	$1.91 ▼ $7.84	$368.86M	0.72	259,456 shs	183,390 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NAUT Nautilus Biotechnology	+20.70%	+16.45%	+29.48%	-51.09%	+67.16%
PACB Pacific Biosciences of California	-2.27%	-2.27%	+12.17%	-4.44%	-1.53%
SLP Simulations Plus	0.00%	-0.05%	+0.38%	+11.70%	+30.08%
TKNO Alpha Teknova	+1.02%	-6.46%	+3.42%	+57.95%	+63.53%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NAUT Nautilus Biotechnology	2.33	Hold	$4.00	257.14% Upside
PACB Pacific Biosciences of California	1.83	Reduce	$1.71	32.75% Upside
SLP Simulations Plus	1.88	Reduce	$17.25	-6.35% Downside
TKNO Alpha Teknova	2.25	Hold	$7.50	7.91% Upside

Current Analyst Ratings Breakdown

Latest NAUT, PACB, SLP, and TKNO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/9/2026	NAUT Nautilus Biotechnology	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$4.00
9/9/2026	PACB Pacific Biosciences of California	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$1.50 ➝ $1.35
8/25/2026	PACB Pacific Biosciences of California	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	PACB Pacific Biosciences of California	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	TKNO Alpha Teknova	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	TKNO Alpha Teknova	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$8.00
8/6/2026	TKNO Alpha Teknova	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
8/5/2026	NAUT Nautilus Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/5/2026	TKNO Alpha Teknova	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$7.00
8/5/2026	TKNO Alpha Teknova	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$7.00
7/17/2026	NAUT Nautilus Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NAUT Nautilus Biotechnology	N/A	N/A	N/A	N/A	$1.24 per share	N/A
PACB Pacific Biosciences of California	$160.01M	2.51	$0.77 per share	1.67	$0.02 per share	64.50
SLP Simulations Plus	$79.18M	4.71	$1.43 per share	12.87	$6.20 per share	2.97
TKNO Alpha Teknova	$40.52M	9.20	N/A	N/A	$1.28 per share	5.43

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NAUT Nautilus Biotechnology	-$59M	-$0.45	N/A	N/A	N/A	N/A	-37.58%	-30.83%	10/27/2026 (Estimated)
PACB Pacific Biosciences of California	-$546.38M	-$0.43	N/A	N/A	N/A	-82.49%	-5,752.12%	-19.52%	11/3/2026 (Estimated)
SLP Simulations Plus	-$64.72M	$0.40	46.05	N/A	N/A	9.88%	13.50%	12.45%	10/29/2026 (Estimated)
TKNO Alpha Teknova	-$17.26M	-$0.31	N/A	N/A	N/A	-38.37%	-24.94%	-16.53%	11/5/2026 (Estimated)

Latest NAUT, PACB, SLP, and TKNO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	TKNO Alpha Teknova	-$0.0843	-$0.06	+$0.0243	-$0.06	$10.95 million	$12.19 million
8/3/2026	Q2 2026	PACB Pacific Biosciences of California	-$0.1280	-$0.14	-$0.0120	-$0.14	$42.90 million	$39.01 million
7/28/2026	Q2 2026	NAUT Nautilus Biotechnology	-$0.1350	-$0.11	+$0.0250	-$0.11	$0.10 million	$0.19 million
7/9/2026	Q3 2026	SLP Simulations Plus	$0.2325	$0.30	+$0.0675	$0.18	$20.90 million	$21.89 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
NAUT Nautilus Biotechnology	N/A	N/A	N/A	N/A	N/A
PACB Pacific Biosciences of California	N/A	N/A	N/A	N/A	N/A
SLP Simulations Plus	N/A	N/A	-100.00%	N/A	N/A
TKNO Alpha Teknova	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NAUT Nautilus Biotechnology	N/A	10.14	10.14
PACB Pacific Biosciences of California	N/A	4.92	4.03
SLP Simulations Plus	N/A	5.54	5.54
TKNO Alpha Teknova	0.21	4.49	3.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
NAUT Nautilus Biotechnology	50.71%
PACB Pacific Biosciences of California	N/A
SLP Simulations Plus	78.08%
TKNO Alpha Teknova	13.81%

Insider Ownership

Company	Insider Ownership
NAUT Nautilus Biotechnology	41.10%
PACB Pacific Biosciences of California	3.70%
SLP Simulations Plus	19.10%
TKNO Alpha Teknova	13.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
NAUT Nautilus Biotechnology	130	127.25 million	74.95 million	Optionable
PACB Pacific Biosciences of California	730	310.83 million	299.33 million	Optionable
SLP Simulations Plus	160	20.23 million	16.36 million	Optionable
TKNO Alpha Teknova	240	53.61 million	46.54 million	Not Optionable

NAUT, PACB, SLP, and TKNO Headlines

Recent News About These Companies

879,786 Shares in Alpha Teknova, Inc. $TKNO Acquired by BlackRock Inc.

September 6, 2026 | marketbeat.com

Alpha Teknova: Ample Manufacturing Capacity At A High Premium

August 24, 2026 | seekingalpha.com

Alpha Teknova Raises Outlook After Record Q2 Revenue at Sidoti Conference

August 19, 2026 | marketbeat.com

Alpha Teknova (TKNO) is a Great Momentum Stock: Should You Buy?

August 19, 2026 | zacks.com

Wall Street Analysts Believe Alpha Teknova (TKNO) Could Rally 35.45%: Here's is How to Trade

August 10, 2026 | zacks.com

Alpha Teknova (TKNO) Stock Moves Higher on Booming Clinical Demand

August 7, 2026 | insidermonkey.com

Teknova targets less than $8M 2026 free cash outflow as it lifts revenue guide to $45M-$47M

August 6, 2026 | seekingalpha.com

Teknova Launches Build-Tek™, a Proprietary AI Reagent Assistant That Allows Customers to Configure Complex Custom Product Requests in Minutes

August 5, 2026 | markets.businessinsider.com

Teknova Reports Second Quarter 2026 Financial Results

August 5, 2026 | globenewswire.com

Teknova to Report Second Quarter 2026 Financial Results on August 5, 2026

July 22, 2026 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Alpha Teknova (TKNO), Arcus Biosciences (RCUS) and Tenaya Therapeutics (TNYA)

June 4, 2026 | theglobeandmail.com

Analysts Offer Insights on Healthcare Companies: Alpha Teknova (TKNO) and REPRO-MED Systems (KRMD)

May 9, 2026 | theglobeandmail.com

Alpha Teknova, Inc. (NASDAQ:TKNO) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

May 9, 2026 | finance.yahoo.com

Alpha Teknova, Inc. (TKNO) Q1 2026 Earnings Call Transcript

May 8, 2026 | seekingalpha.com

Alpha Teknova Charts Cautious Path to 2027 Growth

May 7, 2026 | tipranks.com

Alpha Teknova (TKNO) Q1 2026 Earnings Transcript

May 6, 2026 | finance.yahoo.com

Teknova Reports First Quarter 2026 Financial Results

May 6, 2026 | globenewswire.com

Teknova to Report First Quarter 2026 Financial Results on May 6, 2026

April 22, 2026 | globenewswire.com

Favourable Signals For Alpha Teknova: Numerous Insiders Acquired Stock

March 30, 2026 | finance.yahoo.com

Alpha Teknova (NASDAQ:TKNO) CEO Acquires $55,900.00 in Stock

March 10, 2026 | insidertrades.com

Teknova outlines 20%-25% long-term revenue growth target while investing $2M annually in commercial capabilities

February 27, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAUT, PACB, SLP, and TKNO Company Descriptions

Nautilus Biotechnology NASDAQ:NAUT

$1.12 +0.19 (+20.70%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$1.09 -0.03 (-2.68%)

As of 06:28 AM Eastern

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Pacific Biosciences of California NASDAQ:PACB

$1.29 -0.03 (-2.27%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$1.30 +0.01 (+0.62%)

As of 06:26 AM Eastern

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Simulations Plus NASDAQ:SLP

$18.42 0.00 (0.00%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$18.42 0.00 (0.00%)

As of 09/9/2026 07:30 PM Eastern

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. The company also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, RENAsym, IPFsym, and MITOsym products. In addition, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, it offers creative and insightful consulting services to support its quantitative systems pharmacology/quantitative systems toxicology modelling. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.

Alpha Teknova NASDAQ:TKNO

$6.95 +0.07 (+1.02%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$6.96 +0.00 (+0.07%)

As of 09/9/2026 04:10 PM Eastern

Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NAUT, PACB, SLP, and TKNO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NAUT, PACB, SLP, and TKNO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NAUT, PACB, SLP, and TKNO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAUT, PACB, SLP, and TKNO Company Descriptions

Nautilus Biotechnology NASDAQ:NAUT

Pacific Biosciences of California NASDAQ:PACB

Simulations Plus NASDAQ:SLP

Alpha Teknova NASDAQ:TKNO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NAUT, PACB, SLP, and TKNO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NAUT, PACB, SLP, and TKNO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NAUT, PACB, SLP, and TKNO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAUT, PACB, SLP, and TKNO Company Descriptions

Nautilus Biotechnology NASDAQ:NAUT

Pacific Biosciences of California NASDAQ:PACB

Simulations Plus NASDAQ:SLP

Alpha Teknova NASDAQ:TKNO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools